Prevalence of UGT1A1*28 promoter polymorphism in the omani population: Implications for irinotecan treatment in GI cancer

被引：0
|
作者：
Al Ghoche, A. A. G. [1 ]
Al Zadjali, S. [2 ]
Pullanhi, A. [3 ]
Alfahdi, A. [3 ]
Al-Balushi, A. [2 ]
Al-Mahrouqi, N. [2 ]
Abu Omar, R. [3 ]
Salman, B. [4 ]
Almoundhri, M. [1 ]
机构：
[1] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Oncol Dept, Muscat, Oman
[2] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Res Labs, Muscat, Oman
[3] Sultan Qaboos Univ Hosp, Muscat, Oman
[4] SQCCCRC Sultan Qaboos Comprehens Canc Care & Res, Pharm Dept, Muscat, Oman
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
525P
引用
收藏
页码：S208 / S209
页数：2
相关论文
共 50 条
  • [11] UGT1A1*28 POLYMORPHISM AND VOMITING IN ADVANCED COLORECTAL CANCER
    El Bastawisy, A. E.
    Farid, S. F.
    Bahnasy, A. A.
    El Zeiny, A. M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [12] UGT1A1*28 polymorphism is not associated to irinotecan-induced toxicity in pediatric patients
    de Torres, C.
    Cruz, O.
    Parareda, A.
    Segura, S.
    Mora, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 96 - 96
  • [13] Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients
    Thu Nguyen, Cuc Thi
    Minh Thuy, Nguyen Thi
    Huong, Phung Thanh
    PHARMACOGENOMICS, 2024, 25 (10-11) : 469 - 477
  • [14] Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
    Xu, Jian-Ming
    Wang, Yan
    Ge, Fei-Jiao
    Lin, Li
    Liu, Ze-Yuan
    Sharma, Manish R.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (24) : 3899 - 3903
  • [15] Irinotecan pharmacogenetics in Japanese cancer patients:: Roles of UGT1A1*6 and*28
    Sai, Kirnie
    Sawada, Jun-Ichi
    Minami, Hironobu
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2008, 128 (04): : 575 - 584
  • [16] Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer
    Bajro, Marija Hiljadnikova
    Josifovski, Toni
    Panovski, Milco
    Jankulovski, Nikola
    Nestorovska, Aleksandra Kapedanovska
    Matevska, Nadica
    Petrusevska, Natalija
    Dimovski, Aleksandar J.
    CANCER GENETICS, 2012, 205 (04) : 163 - 167
  • [17] UGT1A1☆6 AND UGT1A1☆28 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE LEUKOPENIA IN JAPANESE PATIENTS WITH LUNG CANCER
    Fukuda, Minoru
    Okumura, Manabu
    Hisatomi, Keiko
    Suyama, Naofumi
    Iwakiri, Tomomi
    Takagi, Akinori
    Nakamura, Yoichi
    Arimori, Kazuhiko
    Kohno, Shigeru
    RESPIROLOGY, 2010, 15 : 37 - 37
  • [18] Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms
    Jian-Ming Xu
    Yan Wang
    Fei-Jiao Ge
    Li Lin
    Ze-Yuan Liu
    Manish R Sharma
    World Journal of Gastroenterology, 2013, 19 (24) : 3899 - 3903
  • [19] The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk
    Duguay, Y
    McGrath, M
    Lépine, J
    Gagné, JF
    Hankinson, SE
    Colditz, GA
    Hunter, DJ
    Plante, M
    Têtu, B
    Bélanger, A
    Guillemette, C
    De Vivo, I
    CANCER RESEARCH, 2004, 64 (03) : 1202 - 1207
  • [20] The impact of UGT1A1*28 and UGT1A1*6 on irinotecan-induced neutropenia in Asian cancer patients receiving weekly and three weekly irinotecan regimens
    Chowbay, B.
    Rao, S. J. Srinivasa Jada
    Cher, B. C. Goh Boon
    Lim, R. Robert
    Teck, W. T. Lim Wan
    Huat, E. H. Tan Eng
    EJC SUPPLEMENTS, 2006, 4 (12): : 136 - 136
12345